AbbVie Reports First-Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Abbvie (ABBV) Weakness Related to Hep-C Data from Gilead (GILD), BMO Capital Says
April 23, 2015 11:47 AM EDTBMO Capital analyst Alex Arfaei weighed in on Abbvie (NYSE: ABBV) following Q1 results. The analyst said Street Hep-C numbers need to come down although the bullish thesis is intact.
Arfaei commented, "ABBV shares are down about 2% as we prepare this note, despite the company reporting strong 1Q15 results. We believe the weakness is likely related to new Hep-C data released from Gilead (NASDAQ: GILD)."
He continued, "A Phase 2... More
